Compare Charter Communications Inc (CHTR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charter Communications Inc vs McKesson Corporation — how do they compare? Charter Communications Inc trades at $157.69 (market cap $18.28B), while McKesson Corporation trades at $899.06 (market cap $102.58B). The key difference: McKesson Corporation is far larger — about 5.6× Charter Communications Inc's market cap, and McKesson Corporation pays a 0.43% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| CHTR | MCK | |
|---|---|---|
Market Cap | $18.28B | $102.58B |
Sector | Media | Health |
52-Week High | $282.74 | $995.69 |
52-Week Low | $123.31 | $659.01 |
Enterprise Value | $114.49B | $109.12B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charter Communications (CHTR) trades at $152.57, down 3.09% on the day, with a bullish technical signal from moving averages but mixed oscillators. The stock shows low valuation multiples with a P/E of 3.97 and P/S of 0.36, supported by a 9.05% net income margin and strong operating cash flow of $16.08B in 2025. Recent Q2 2026 earnings beat expectations with EPS of $10.66 versus $9.98 estimated, though revenue declined 1.7% year-over-year. News highlights debt refinancing activities and competitive pressures in broadband.
The outlook remains cautious due to subscriber losses and fiber competition, but the extreme valuation discount and aggressive buybacks offer potential upside. Risks include high debt leverage at $93.21B long-term and persistent industry headwinds. Analyst consensus is mixed with a $166.18 price target, suggesting 9% upside from current levels.
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
